Immuno-oncologyDupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but are associated with treatment-limiting immune-related cutaneous adverse events (irCAEs). Immune checkpoint inhibitor-related bullous pemphigoid (irBP), a severe, blistering irCAE occurs in 0.3%-1.5% of patients receiving ICI therapy. While systemic steroids can be effective, they are associated with significant toxicity and may mitigate -immunotherapy antitumor efficacy. Consequently, steroid-sparing therapies are needed. Dupilumab, an IL-4 and IL-13 receptor antagonist, has demonstrated efficacy in non-ICI-related BP and appears promising for managing irBP.

Methods

We conducted a retrospective review of patients treated with dupilumab for irBP from April 2020 to April 2024. Clinical data,

SUBMITTER: Nykaza I 

PROVIDER: S-EPMC12404300 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature